Background and Purpose-Angioplasty and stenting is increasingly being used for the treatment of intracranial stenoses.
S
evere intracranial atherosclerosis with concomitant stenosis is responsible for approximately 5% to 10% of all strokes in mixed patient populations and thereby contributes significantly to the huge medical, social, and economic problems associated with cerebral ischemia being the third leading cause of mortality in industrialized countries. In Asian populations intracranial stenoses are even the most commonly found vascular lesions. 1 Although retrospective studies have indicated that up to 50% of patients with a recently symptomatic intracranial stenosis experience recurrent symptoms, 2 the risk of recurrent stroke in this patient population was significantly lower in the prospective, National Institute of Health-sponsored, multicenter WarfarinAspirin Symptomatic Intracranial Disease (WASID) trial. 3 Nonetheless, 14% and 23% of the patients with a TIA or stroke attributable to a high-grade intracranial stenosis had a further ipsilateral ischemic stroke over the next year in that trial despite medical therapy. These figure have spurred the enthusiasm for endovascular approaches, including percutaneous transluminal balloon angioplasty (PTA), as well as the use of balloon-mounted or self-expanding intracranial stents to treat this potentially harmful disease. 4 -6 On the other hand, the endovascular management of intracranial disease is associated with an appreciable number of potential complications, including local thrombosis, thromboembolism, vessel ruptures or dissections. To date, the composite stroke and death rates during intracranial stenting in case series and small trials have varied widely, ranging from 0% 7, 8 in some to more than 30% in others. 9, 10 Especially the latter complication rates raise the question about whether intracranial stenting improves the natural course of this disease. Although this uncertainty can only be solved in a prospective randomized trial comparing interventional with medical therapy, it is unlikely that these data will be available in the next few years. Therefore, current treatment decisions are usually based on the results of case series and registries, many of which have been published in the past few years.
Against the background of an increasing amount of data on this topic and the rapid development within this endovascular field, we systematically searched for all reports dealing with angioplasty and stenting for symptomatic, intracranial stenoses of atherosclerotic origin to (1) determine the immediate and long term outcomes, as well as the durability of this procedure, and (2) analyze the impact of procedural and patient-related variables on outcome.
Materials and Methods

Search Strategy
Two independent observers (K.G. and A.K.) performed an electronic literature search with Entrez PubMed NIH. A combination of key words including intracranial, cerebral, internal carotid, basilar or vertebrobasilar arteries, and angioplasty or stent was used to extract all relevant abstracts. Studies were included if published between January 1998 (threshold chosen after publication of the first use of a stent in the intracranial circulation to treat an aneurysm by Higashida and coworkers 11 ) and April 2008 inclusive. Animal studies as well as case reports, letters/editorials, and comments and reviews that did not contain original data were excluded from further analysis. The abstract of each remaining article was carefully studied to detect appropriate publications, and if there was any suggestion of the data we looked for, the full text was retrieved. Furthermore, reference sections of all relevant articles were checked for further leads. Additionally, a third observer (S. 
Eligibility Studies
Studies were included if the following criteria were fulfilled: (1) they were written in English; (2) the study comprised more than 5 patients with intracranial angioplasty and stent procedures; (3) all patients had been treated for an atherosclerotic intracranial stenosis (internal carotid, middle cerebral, vertebral or basilar artery) greater than 50% determined on conventional angiography; and (4) periinterventional complications (stroke or death) were reported.
Articles were excluded if only angioplasty without stent placement had been performed or the complication rate of the stented arteries could not be extracted. In addition, studies in which the majority of patients had been treated with acute ischemic events attributable to acute vessel occlusions were excluded. In case of multiple publications from the same study population with overlapping recruitment periods we used the most recent publication.
Data Extraction
For all studies the following data were extracted independently by two observers (K.G. and A.K.) by use of a predefined electronic data sheet: (1) year of publication, recruitment period, number of patients, and treated arteries; (2) patient characteristics (age, sex, symptomatic or asymptomatic intracranial atherosclerotic disease); (3) the degree of stenosis; (4) the location of the stenosis (ie, anterior versus posterior circulation); (5) in patients with a symptomatic stenosis time to treatment; (6) type of stent used; (7) number of procedural failures; (8) degree of stenosis posttreatment; (9) the average follow-up time; (10) periprocedural stroke and death rates within 30 days or during follow-up; (11) rates of restenosis (Ͼ50%) of the involved vessels during follow-up and classified as symptomatic or asymptomatic; and (12) the number of reinterventions performed.
Articles that met all inclusion criteria but specific data extraction was not possible were marked as "NG" (not given). 
Data Analysis
Results
Studies
Our electronic literature search with Entrez PubMed NIH is summarized in Figure 1 and resulted in 86 abstracts of which full text articles were retrieved. Forty-three studies fulfilled all inclusion criteria and were therefore used for further analysis. A total of 12 articles had to be excluded because they reported on patients already used in other publications from the same institution (see online supplemented material). The main characteristics of the remaining 31 studies included in this analysis 4 -10,12-32,39 -41 are summarized in Table 1 .
Patient and Treatment Characteristics
In a total of 1134 patients (76% men; mean age 63.6 years Ϯ3.7) 1177 arteries had been treated. The majority of patients had been treated after a symptomatic event (98%, range from 76.9% to 100%), which was transient in 44% and permanent in 56%.
The lower limit of stenosis for patient inclusion varied from 50% to 80% according to WASID-criteria between the studies. The mean severity of stenosis before treatment ranged from 67% to 92% (mean Ϯ SD: 77.7Ϯ7.4) and from 0% to 38% (13.9Ϯ10.5) after treatment, respectively. Nearly half of these stenoses (48.5%) were located in the anterior circulation (intracranial portion of the internal carotid artery The technical success rates varied from 71% to 100% with a median of 96.9% (IQR: 90.0% to 100%) across all studies. In 77.0% (nϭ906) of the procedures balloon-mounted stents were used, and in 23.0% (nϭ271) 4, 17, 22, 23 of all procedures a self-expanding stent had been used. The mean degree of stenosis before treatment was comparable between balloonmounted and self-expandable stents (78.0%Ϯ7.9% and 75.8%Ϯ4.3%, Pϭ0.6), whereas the residual degree of steno- 
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sis after treatment was significantly higher after the use of self-expandable stents than after the use of balloon-mounted stents (29.3%Ϯ7.6% and 10.9%Ϯ8.0%, PϽ0.001). Data of the different stent-types used was available for 1047 procedures. In 66 (6.3%) of these procedures drug-eluting stents were used, all of them were balloon-mounted.
Periprocedural Clinical Outcome
The combined periprocedural minor or major stroke and death rates ranged from 0% to 50% with a median of 7.7%
(IQR: 4.4%-14.3%). Within the anterior circulation the complication rates ranged from 0% to 30% with a median of 5.1% (IQR: 0% to 16.7%) and from 0% to 50% with a median of 8.3% (IQR: 0% to 15.2%) within the posterior circulation, respectively. A total of 55 (12.1%) stroke or death complications could be attributed to the posterior and 28 (6.6%) to the anterior circulation (PϽ0.01, OR: 1.94, CI: 1.21 to 3.10; Table 2 ), whereas an additional 24 events could not be attributed to any of these arterial territories. Periprocedural complications did not differ between the studies in which a balloon-mounted compared with those in which a self-expandable stent had been used for treatment (9.5% versus 7.7%, Pϭ0.470, OR: 1.15, CI:0.76 to 2.05). With respect to the periprocedural complication rates there was no significant difference between the studies which had used a higher degree of stenosis as inclusion criteria compared to those which had used lower threshold (Ͼ70%: nϭ271, 26 complications versus Ͻ70%: nϭ748, 52 complications; 9.59% versus 6.95%, Pϭ0.18; OR: 1.42, CI: 0.87 to 2.32).
Follow-Up
The clinical follow-up and method of vessel imaging of the studies included in this review are summarized in Table 3 .
The clinical follow-up time reached a maximum mean follow-up time of 43.5 months in one study, 24 with a mean follow-up time across all studies of 13.5 months. The prob- No. of patients with follow-up imaging is given in parenthesis. MMD indicates minor, major stroke, and death; Angiography, conventional digital subtraction angiography; CTA, computed tomography angiography; MRA, magnet resonance angiography; TCD, transcranial Doppler sonography.
ability of a follow-up event (stroke or death) is visualized in Figure 2 .
Follow-up data of the treated vessels to determine a Ͼ50% restenosis was found to be very heterogonous between the studies and varied from 3 to 21 months with a median follow-up time of 6 months (IQR: 5.3 to 11). 4,5,7,9,12-16,18 -22,24 -32 In the majority of studies, the occurrence of a restenosis was based on routinely scheduled investigations (angiography, CTA, MRA, transcranial doppler ultrasound), whereas others were done only if a symptomatic event occurred. The rate of restenosis (defined as Ͼ50% according to WASID-criteria) ranged from 0% to 50% with a median of 3.9% (IQR: 0% to 19.2%). A total of 77 (14.4%) restenoses were detected among 535 patients (45.5% of treated vessels under review) who were investigated in long-term follow-up. Of these, 32.7% were symptomatic (TIA, stroke, or death) with a nonsignificant trend of a higher occurrence of a symptomatic restenosis after the use of a balloon-mounted stent than after using a self-expandable stent (41.6% versus 12.5% Pϭ0.080, OR: 5.00 CI:1.08 to 22.33). On the other hand, there was a significant difference (log-rank test; PϽ0.001) in the occurrence of any restenosis (ie, symptomatic or asymptomatic) between patients treated with a balloon-mounted (nϭ443; restenosis rate: 13.8%, mean follow-up time: 8.7 months) compared with those who had been treated with a selfexpandable stent (nϭ92; restenosis rate: 17.4%, mean follow-up time: 5.4 months; Figure 3 ).
Discussion
On the basis of a systematic review of the literature and a total of 1177 procedures, we demonstrate that intracranial angioplasty and stent placement is principally feasible and has a high initial procedural success rate. However, adverse events, of which the majority occurs within the first weeks of the procedure, vary widely among different centers and may also depend on the location of the stenosis. Moreover, our data indicate that intracranial stenting is associated with a significant rate of restenoses, which appears to be higher after the use of self-expandable than after the use of balloon-mounted stents.
In the past few years, many small case series and single center studies on intracranial stenting have been published, reflecting the increased enthusiasm for the application of this interventional technique. Although it is beyond doubt that the use of intracranial stenting needs to be compared with medical treatment in a prospective randomized trial to answer the question about whether or not intracranial stenting improves the natural history of the disease, the collective information from these observational studies is useful as a current source of decision making in everyday clinical practice until the results of such a trial are available.
In the WASID trial the 1 year rate of ischemic stroke in the territory of the stenotic artery among patients with a symptomatic intracranial stenosis Ͼ50% treated with either aspirin or warfarin was approximately 12%. 3 An indirect comparison with these data clearly indicates that the periprocedural complication rates were unacceptably high (up to 50%) in some centers. Especially, intracranial vertebral and basilar artery stenting have produced mixed results. In fact, we found significantly higher periprocedural complication rates in the posterior compared with the anterior circulation. In contrast, the stroke rates in the territory of the symptomatic artery were comparable in the anterior versus the posterior circulation (14% versus 13%) during a mean duration of follow-up of 1.8 years in the WASID study. 3 In consideration of these results, patients with a stenosis in the posterior circulation might not necessarily be ideal candidates for an interventional treatment. From a theoretical point of view, the small diameters and angulation of the vertebral artery, which are associated with a higher degree of technical complexity, could contribute to the increased periprocedural complication rates observed in the posterior circulation. In addition, it is conceivable that even "small" embolic complications within the brain stem are likely to cause more harm to the patient than those occurring within the cerebral hemispheres. Finally, the probability that a stent might cover the ostia of a perforator and thereby lead to a subsequent stroke is higher in the posterior than in the anterior circulation.
The risk for a subsequent stroke within the WASID-Trial was highest in the subgroup of patients with a stenosis Ͼ70%. 33 Because the periprocedural complication rates in this review did not significantly depend on the degree of stenosis, at least using a cut-off value of Ͼ70% versus Ͻ70%, patients with a high-grade stenosis might especially profit from an interventional therapy. A prospective randomized trial comparing intensive medical with interventional therapy in this patient population is currently underway. 34 Our data analysis revealed that the vast majority of adverse events occurs within the first few weeks after intracranial stent placement. A similar finding has also been reported in the recently published NIH registry on the use of the Wingspan stent for symptomatic high-grade intracranial arterial stenosis, which is also included in our review. 4 In that registry the stroke and death rate within 24 hours of the stenting procedure was 6.2% and 9.6% within 30 days, respectively. The rate of any stroke or death within 30 days or stroke in the territory of the stented artery beyond 30 days was 14% at 6 months. Compared with "best medical therapy" the relatively high periprocedural complication rates are likely the major drawback of intracranial stenting, which has spurred the efforts for improving the stent devices. In this scenario, there has been an increased enthusiasm about the use of highly flexible self-expanding stents such as the Wingspan stent system in the past few years. In case of the Wingspan system, the atherosclerotic lesion is initially predilated with an undersized balloon at low pressures, followed by placement of a self-expanding nitinol microstent across the lesion. Although it has been anticipated that the use of these devices has the potential to reduce mortality and morbidity after the procedure, the periprocedural complication rates were not significantly different between the studies in which a balloonmounted compared with those in which a self-expandable stent had been used for treatment.
Compared with the relatively good durability of angioplasty and stenting procedures within the extracranial carotid artery, 35 a high incidence of restenoses appears to be a major drawback of intracranial stenting. Recent studies suggest that especially younger patients treated with self-expandable stents within the anterior circulation have a high risk for this complication. 36, 37 Theoretically, self-expandable stents have the capability of further remodeling the target vessel to maintain patency after deployment without the need for postdilatation and may thus reduce the restenosis rates. Contrary to this notion, our data clearly indicate that the use of these devices is associated with higher degrees of residual stenosis immediately after treatment. At least partially, this finding could be attributable to an increased susceptibility of atherosclerotic plaques to protrude into the remodeled vessel because of the high flexibility of self-expandable stents. This could also account for the higher restenosis rates observed in patients treated with these devices compared to those who had been treated with balloon-mounted stents. Taking into account that 33% of all restenoses were symptomatic (TIA or stroke) within this review, a tight follow-up of all patients treated with intracranial stenting is clearly necessary. However, the question of which technique should be used to follow-up these patients remains to be resolved. Although conventional digital intraarterial subtraction angiography is currently considered to be the gold standard, this invasive technique is associated with a measurable neurological complication rate. CT angiography and MR angiography are known to suffer from considerable artifacts that often prevent proper assessment of the stent lumen. In this scenario, preliminary studies indicate that angiographic CT with intravenous administration of contrast medium could become an alternative minimally invasive technique for the follow-up of these patients. 38 
Study Limitations
A review of the literature on intracranial angioplasty and stenting is methodologically challenging and also clearly demonstrates the limitations of the currently available data. The vast majority of data on intracranial stenting stems from retrospective case series. In fact, only 14 studies within our review have been published, which provide prospective data on long-term outcome after this procedure and to date no prospective trial has compared stenting with best medical therapy. Moreover, there was a wide heterogeneity in the study designs, treatment regimens (eg, blood pressure management and medical treatment), material, and patient populations. As in any field of medical sciences, publication biases likely exist toward selective submission and acceptance of studies with good results over studies with poor results. Because it is very likely that any future trial will compare best medical therapy with intracranial stenting rather than angioplasty alone, it should be pointed out that we focused on studies dealing with intracranial stenting. Several studies did not report separate results for intracranial angioplasty with versus without stent placement and were thus excluded from our analysis.
In the majority of studies summarized in this review, neither an independent neurological evaluation nor a systematic clinical follow-up and screening for restenoses was performed. The lack of a systematic vessel follow-up and different screening techniques limits the validity of our restenosis rates, as well as the observed difference between self-expandable and balloon-mounted stents.
Finally, this review concerned a newly developed treatment. Similar to other surgical or endovascular techniques such as carotid artery stenting, increasing expertise will likely influence the complication rates. Although we could not determine the effect of learning on outcome across all studies, a recently published multicenter trial clearly identified a significant association between patient volume and outcome after intracranial stenting. 4 
Conclusion
In summary, stent placement of the intracranial arteries is principally feasible and has a high initial procedural success rate. However, adverse events, of which the majority occurs within the first weeks of the procedure, vary widely among different centers and depend on the lesion location. Moreover, this procedure is associated with a high rate of restenoses, and to date there is no clear impact of new stent devices on outcome. Currently, intracranial stent placement is still an investigational technique, which should only be performed in high-volume centers and urgently needs to be compared with best medical therapy in a prospective randomized trial. Such a trial is currently underway. 34 
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